Navigation Links
Pfizer Appoints Mikael Dolsten President of Worldwide Research and Development
Date:5/26/2010

NEW YORK, May 26 /PRNewswire-FirstCall/ -- Today, Pfizer Inc. (NYSE: PFE) named Mikael Dolsten, M.D., PhD, President of Pfizer Worldwide Research and Development, as the Company completes its integration of these functions following the Wyeth acquisition.  Dr. Dolsten previously led Wyeth's Research and Development organization from May 2008, and after the close of the Wyeth acquisition was named President of Pfizer's BioTherapeutics Research & Development.  Prior to his appointment at Wyeth, Dr. Dolsten held key leadership roles in R&D at Boehringer Ingelheim and AstraZeneca.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO )

With this appointment, Dr. Dolsten will now lead all of research at Pfizer, as well as development of all compounds through Phase 2, or 'proof of concept.'  Late-stage clinical development will continue to be led by clinical teams throughout the Worldwide Biopharmaceutical Businesses, as announced in April 2009.

"Since closing the Wyeth acquisition we have rapidly advanced integration, completing the pipeline portfolio review, finalizing decisions regarding our R&D network very quickly after close, and steadily progressing the pipeline.  Rapid integration has been enhanced by strong  and steady collaboration between the two legacy R&D groups -- making the consolidation under one leader a natural and progressive step to take at this point," said Jeffrey Kindler, Pfizer's chairman and chief executive officer.

The newly named Pfizer Worldwide Research & Development organization will maintain an R&D structure that supports excellence in small molecules, large molecules and vaccine research and development.  It will include biotherapeutics research and development, focused on large molecules and biotechnologies; pharmatherapeutics research and development, focused on small molecules; and vaccines research and development.  Pfizer adopted a novel R&D model following the Wyeth acquisition to foster diversity of talent, assets and culture, as well as the empowerment and accountability of research leaders across R&D.  Pfizer initially implemented this model with a two-division structure (BioTherapeutics and PharmaTherapeutics) to ensure the progress and steady integration of both legacy organizations.  Due to the speed and effectiveness of the integration, Pfizer is now able to implement a diversified R&D platform with the same breadth and research programs, under the consolidated leadership of Dr. Dolsten.

"Mikael Dolsten is an exceptional scientist who is highly regarded and committed to bringing new preventative measures, treatments and cures to people.  Mikael's scientific expertise, vision for R&D and commercial mindset have distinguished him at Pfizer and uniquely qualify him to lead our R&D colleagues and advance our pipeline.  Having all of Pfizer's research conducted under Mikael's leadership will enrich the alignment between our research programs and commercial teams to address important unmet medical needs and deliver the next generation of medicines," said Mr. Kindler.  

"I am excited to have the opportunity to align the tremendous science that is in every corner of Pfizer to bring forward medicines and vaccines that transform lives," said Dr. Dolsten.  "We have great skills in science, we have industry-leading technologies, and I am very proud of our R&D pipeline.  I look forward to working with our leaders to advance our effort to become the world's premier biopharmaceutical R&D group."

Pfizer also announced today the resignation of Martin Mackay, President, PharmaTherapeutics Research & Development, who will leave the company effective immediately.  Dr. Dolsten will expand the role of Rod MacKenzie, PhD, who is currently Senior Vice President and Head of Worldwide Research for PharmaTherapeutics R&D.  In addition to his current responsibilities leading small molecule research, Dr. MacKenzie will add responsibility for Asia R&D strategy, as well as small molecules pharmaceutical science.  

"We thank Martin Mackay for his many accomplishments and greatly appreciate all he has done to help us develop world-class scientists at Pfizer," added Mr. Kindler.  "I know Mikael will work closely with Rod and all of our leaders across PharmaTherapeutics and BioTherapeutics to ensure continuity of strategy and progress, as we continue to build our science base at Pfizer," said Mr. Kindler.  

"Rod's ability to transform pharmaceutical research has impressed me tremendously," said Dr. Dolsten.  "I am excited he has accepted to take on an expanded new role, and I look forward to a strong partnership to advance Pfizer R&D - and to serve people who rely on science and medicine for healthier and more productive lives."

Pfizer Inc.: Working together for a healthier world™

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life.  We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals.  Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products.  Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.  For more than 150 years, Pfizer has worked to make a difference for all who rely on us.  To learn more about our commitments, please visit us at www.pfizer.com


'/>"/>
SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
4. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. MannKind Addresses Pfizers Announcement Regarding Exubera
8. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
11. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... PHILADELPHIA , March 30, 2017  Lannett Company, ... the company voluntarily made a $25 million payment against ... $25 million payment, combined with the $75 million payment ... us approximately $5.5 million in annualized cash interest expense, ... executive officer of Lannett.  "Our business is solid and ...
(Date:3/29/2017)... Research and Markets has announced the addition of the ... (Insource IONM, Outsource IONM), By Region And Trend Analysis From ... ... Intraoperative Neuromonitoring (IONM) market is expected to reach USD 3.6 ... witness significant growth in the forecast period, which can be ...
(Date:3/29/2017)... NEW YORK , March 29, 2017 Global ... cross US$ 3 billion by 2021, growing at a CAGR ... containing iron prescribed by a doctor to treat anemia or ... the iron level in the body. However, in some cases, ... in the body and intravenous (IV) iron therapy comes into ...
Breaking Medicine Technology:
(Date:3/30/2017)... ... ... inventor and manicurist from Greet, S.C., wants to offer people a new way to care ... and healthy feet, so I know the importance of proper foot care," he said. "In ... FOOT-TRAN SYSTEM." , The FOOT-TRAN SYSTEM enables a user to clean and exfoliate the bottoms ...
(Date:3/30/2017)... ... 30, 2017 , ... This morning, more than 275 medical ... support for an independent Vaccine Safety Commission. Five of the signers of the ... hold a press conference at 9:00 AM Friday, March 31 at the ...
(Date:3/29/2017)... San Diego, CA (PRWEB) , ... March 29, 2017 , ... ... meningiomas(1,2), and up to 300,000 people each year develop other types of metastatic brain ... spread quickly throughout the brain(3). As efforts focus on finding more effective treatment options, ...
(Date:3/29/2017)... ... ... main cause of hay fever in the United States, with an estimated 95 percent of ... July each year; with the worst time for sufferers being June and July. , ... provide an effective defense against grass pollen; they are proven in independent studies to trap ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sublime Naturals and its ... Life" or "Wonder Spice", it has been used for thousands of years. , "The ... says Heshelow, author of " Turmeric: How to Use it For Your Wellness. Overcome ...
Breaking Medicine News(10 mins):